Global experience with ixabepilone in breast cancer

Virginia G. Kaklamani, Binge H. Xu, Henry L. Gomez

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Ixabepilone approval in a number of countries across the world as monotherapy and in combination with capecitabine has led to widespread uptake in the later-line breast cancer setting. However, individualized data for ixabepilone in different ethnic groups are limited. Overall, data from small numbers of ethnic subgroups including Hispanic, Japanese and Chinese patients have revealed no clinically significant variation in the disposition, efficacy or tolerability of ixabepilone from that established in pivotal trials. Global use of ixabepilone, while usually along the lines of standard practice, may vary because of local regulatory decisions, clinical practice guidelines and cost considerations. Further information on the global patterns of use of ixabepilone will assist in optimizing the use of this novel therapy.

Original languageEnglish (US)
Pages (from-to)683-692
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number5
StatePublished - May 2011
Externally publishedYes


  • anthracyclines
  • ethnic groups
  • global
  • ixabepilone
  • pretreatment
  • resistance
  • taxanes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Global experience with ixabepilone in breast cancer'. Together they form a unique fingerprint.

Cite this